A Blood Test That Spots 12 Deadly Cancers Just Cleared Its Biggest Hurdle Yet

The Numbers That Matter (and the One That Doesn't)

Let's start with the good stuff. In PATHFINDER 2, the test delivered a specificity of 99.6%, which means the false-positive rate was under 0.4%. When the test says "cancer signal detected," it's right about 60% of the time (a positive predictive value of 60.3%). And when it finds something, it can correctly identify where the cancer originated more than 90% of the time.

That last number matters a lot. Finding cancer is one thing; knowing it's in the pancreas versus the lung tells doctors where to look next. It's like getting a GPS pin instead of just an alarm.

Sensitivity, the test's ability to catch cancers that are actually there, was 39.3% across all cancers in PATHFINDER 2. That sounds low until you realize it jumped to 69.8% for the 12 cancers responsible for two-thirds of U.S. cancer deaths. This isn't a test that catches everything. It's a test that's tuned to catch the deadliest ones.

The NHS-Galleri trial painted a similar picture. Specificity hit 99.55%. Episode sensitivity was 30.7% across all cancers but climbed to 54.7% for those same 12 prespecified cancer types. And at ASCO 2026, Grail showed that Stage IV diagnoses of those deadly cancers dropped with each successive screening round: 9% in the first, 22% in the second, and 26% in the third.

The Elephant in the Room

Now for the uncomfortable part. NHS-Galleri's primary endpoint, the main thing it was designed to prove, was a statistically significant reduction in combined Stage III and IV cancer diagnoses. It missed.

The test caught cancer at roughly four times the rate of standard screening alone, and those encouraging stage-shift trends in the deadliest cancers are genuinely exciting. But the trial didn't deliver the clean "this saves lives" headline that regulators (and investors) crave.

This is exactly why the FDA asked its advisers to wrestle with the "early detection" label. Detecting more cancers earlier is great. Proving that earlier detection actually reduces deaths is a much harder bar to clear, and Galleri hasn't cleared it yet.

It's a bit like building a fire alarm that goes off sooner than any competitor; you can prove it detects smoke faster, but you haven't yet proven that the faster alarm actually leads to fewer houses burning down.

Why Tomorrow's Vote Could Reshape All of Diagnostics

This is the first time an FDA advisory committee has ever evaluated a multi-cancer early detection blood test. Full stop.

That makes tomorrow's panel meeting about far more than Grail. Whatever framework the Molecular and Clinical Genetics Panel establishes (what evidence counts, what labeling is appropriate, what post-market studies are needed) becomes the template for everyone who follows.

The competitive lineup is deep. Exact Sciences launched its Cancerguard MCED blood test in September 2025. Guardant Health and ClearNote Health are also building or advancing their own versions. The broader liquid biopsy market is estimated at anywhere from $7 billion to over $14 billion in 2026, depending on how you define the boundaries.

Every one of those companies is watching tomorrow's meeting like hawks. A favorable vote with clear guardrails would give the entire category a regulatory roadmap. A rejection or a muddled outcome could set things back years.

What Happens Next

A few things to keep in mind. The advisory committee's vote is a recommendation only; the FDA makes the final approval decision separately. A positive vote doesn't guarantee approval, and a negative vote doesn't kill the application (though it certainly wouldn't help).

Even if Galleri eventually earns FDA approval, separate coverage and reimbursement decisions will determine whether insurance pays for it. Clinical guidelines from organizations like the U.S. Preventive Services Task Force would also need to evolve before MCED tests become standard-of-care screening.

But the signal from FDA staff reviewers was about as clean as you could hope for. No safety red flags. No accuracy concerns. No methodological objections. The only real debate left is about what to call it.

For a category that could eventually screen millions of healthy adults for dozens of cancers with a single blood draw, that's a pretty good place to be standing the night before the biggest regulatory moment in its history.

Sarepta's Worst Week Just Rewrote the Gene Therapy Playbook

Sarepta slapped a black box warning on its Duchenne gene therapy Elevidys and cut 36% of its workforce in one brutal announcement. The fallout raises hard questions about the commercial future of accelerated-approval gene therapies in rare disease.